Plasminogen activator for the treatment of acute inflammatory and chronic interstitial lung diseases
Production of a recombinant chimeric fusion protein, consisting of human plasminogen activator (urokinase or u-PA) and human hydrophobic surfactant protein (SP-B, SP-C).<br>
Persistent suppression of alveolar fibrinolytic activity and the resulting permanent intra-alveolar fibrin deposition play an important pathomechanistic role in acute inflammatory and chronic interstitial lung diseases. In this process, the polymerization of fibrinogen to fibrin in the presence of lung surfactant causes incorporation of the surfactant into the growing fibrin matrix, which is associated with loss of surface activity, an altered fibrin structure, and enhanced resistance of fibrin to fibrinolytic proteases. In addition, the blocking of u-PA dependent processes is also linked with reduced activation of hepatocyte growth factor (HGF), which protects the epithelium.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
‘Smart’ contact lenses could someday enable wireless glaucoma detection
Most people with early-stage glaucoma don’t know they have it, even though early treatment is key to reducing vision loss. While detecting a subtle increase in eye pressure helps doctors…
New tech may lead to smaller, more powerful wireless devices
Good vibrations… What if your earbuds could do everything your smartphone can do already, except better? What sounds a bit like science fiction may actually not be so far off….
Caution, hot surface!
An international research team from the University of Jena and the Helmholtz Institute Jena are demystifying the mechanisms by which high-intensity laser pulses produce plasma on the surface of solids….
